Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 1,738 trials

Dementia with Lewy Bodies: Ambroxol Study

We are investigating whether Ambroxol can improve cognitive and functional abilities in people with early Dementia with Lewy Bodies. The study also looks at its effects on sleep disturbances and other related symptoms.

Dementia with Lewy Bodies1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessStandard MedicinesNeurologyPsychiatry

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Colorectal Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons detect brain metastases from colorectal cancer during surgery. This study aims to see how well it works and its safety for patients.

Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncology

Rectal Cancer Surgery: SGM-101 Imaging Study

We are testing a new imaging agent, SGM-101, to see if it helps surgeons better detect rectal cancer during surgery. This study is for patients with locally advanced or recurrent rectal cancer who are undergoing curative surgery.

Rectal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Rectal Polyps: SGM-101 Fluorescent Tracer Study

We are investigating a new imaging technique using SGM-101 to help identify cancerous and non-cancerous tissues in patients with rectal polyps. This study aims to improve how doctors detect early-stage rectal cancer.

Early Rectal Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Locally Advanced Rectal Cancer: Dostarlimab and Radiotherapy

We are studying a new treatment combining dostarlimab and short-course radiotherapy for patients with specific types of rectal cancer. The goal is to see if this approach helps improve treatment success and quality of life.

Locally Advanced Rectal Cancer with Genetic Deficiencies>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Metastatic Non-Small-Cell Lung Cancer: LN-145 Treatment Study

We are investigating whether LN-145, a type of immune cell therapy, is safe and effective for patients with metastatic non-small-cell lung cancer. The study will assess how well it works in shrinking tumors and improving patient outcomes.

Metastatic Non-Small-Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hyperbaric Oxygen Therapy for Sudden Hearing Loss

We are studying whether adding hyperbaric oxygen treatment to standard care improves hearing in people with sudden sensorineural hearing loss. The trial will also look at quality of life and safety of this treatment approach.

Sudden Hearing Loss3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOtolaryngology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Post-Stroke Spasticity: Dry Needling vs. Botulinum Toxin

We are exploring how Dry Needling and Botulinum Toxin type A affect spasticity in the lower limbs of stroke survivors. The study will also look at safety, muscle function, and quality of life.

Spasticity after Stroke3-6 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Tezepelumab for Progressive Pulmonary Fibrosis

We are studying whether Tezepelumab can help reduce symptoms and improve lung function in people with progressive pulmonary fibrosis and high eosinophil levels. This trial compares the medication to a placebo to evaluate its effectiveness.

Interstitial Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePulmonology

Neuroendocrine Neoplasms: Metronomic Temozolomide Study

We are investigating the effects of low-dose Temozolomide in patients with advanced neuroendocrine neoplasms who are not fit for traditional treatments. The goal is to see if this approach can improve survival and quality of life.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Advanced Melanoma: Relatlimab with Nivolumab Study

We are investigating whether combining Relatlimab with Nivolumab helps people with untreated advanced melanoma live longer and have better outcomes than Nivolumab alone.

Metastatic Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Hip Replacement: Antibiotic Impregnated Bone Graft Study

We are investigating whether a new antibiotic-infused bone graft can reduce the risk of infection after hip replacement surgery. This study compares it to a standard graft to see which is more effective and safe.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Cirrhosis Treatment: Efinopegdutide Study

We are testing efinopegdutide in adults with compensated cirrhosis caused by metabolic dysfunction. The study aims to see if it can reduce liver fat and improve liver health compared to a placebo.

Non-alcoholic Steatohepatitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesEndocrinologyHepatology

Acute Graft Versus Host Disease: Siltuximab Treatment

We are studying the effects of siltuximab combined with corticosteroids for patients with severe acute graft versus host disease affecting the liver and gut. The goal is to see if this treatment is effective and safe for first-line therapy.

Acute Graft Versus Host Disease (GVHD)>2 yearsEfficacy phase (II)HematologyInternal Medicine

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Cognitive Impairment in Parkinson's: Donepezil Study

We are studying whether donepezil can improve cognitive function in people with mild cognitive impairment due to Parkinson's disease. The trial will also evaluate its effects on mental health and quality of life.

Parkinson's Disease6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Lymphoma Treatment: MK-3475A Study

We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.

Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Primary Mediastinal Large B-cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology